Cell Dissociation Market Size, Share & Trends Analysis By Product, By Tissue, By Type, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Cell Dissociation Market projected to be worth USD 881.48 million by 2030.
According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.
Impact of COVID-19 on the Cell Dissociation Market
The outbreak of COVID-19 has a positive impact on the growth of the market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Tissue, By type, By End-User, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation
Driver:
Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.
Restraint:
Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.
Opportunity:
Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.
Challenges:
Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.
Global Cell Dissociation Market, By Product:
Based on the Product, Global Cell Dissociation Market is segmented as;
Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.
Global Cell Dissociation Market, By Tissue:
Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).
Global Cell Dissociation Market, By Type:
Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.
Global Cell Dissociation Market, By End-User:
Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.
Global Cell Dissociation Market, By Region:
North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.
According to SPER Market Research, the Cell Dissociation Market estimated to reach USD 881.48 million by 2030 with a CAGR of 13.5%. Growing occurrence of cell-based research, the growing figure of pharmaceutical and biotechnology companies; these are the fuel to the expansion of the market.
Impact of COVID-19 on the Cell Dissociation Market
The outbreak of COVID-19 has a positive impact on the growth of the market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Tissue, By type, By End-User, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered Abeomics, AcceGen, Alstem, Becton, Biological Industries, Capricorn Scientific, Central Drug House, Cytiva, Dickinson and Company, Gemini Bio, Genlantis, Innovative Cell Technologies, Miltenyi Biotec, Neuromics, PromoCell GmbH, Roche Diagnostics, STEMCELL Technologies, Thermo Fisher Scientific, VitaCyte, Worthington Biochemical Corporation
Driver:
Increasing research & development activities in biopharmaceutical companies, encouraging funding scenario for cancer research, growing occurrence and incidence of chronic and infectious diseases, growing focus on personalized medicine, growing government funding for cell-based research; are the key drivers for the market expansion.
Restraint:
Costly cell-based researches, short of of infrastructure for cell-based research in emerging economies, can restraint the expansion of the market.
Opportunity:
Growth opportunities in emerging markets, development in stem cell research, appearance of advanced tissue dissociation enzyme products, recognition of enzyme-free dissociation products over enzymatic dissociation products.
Challenges:
Survival of small players and new entrants, ethical concerns regarding research in cell biology, are the challenges of the market.
Global Cell Dissociation Market, By Product:
Based on the Product, Global Cell Dissociation Market is segmented as;
Enzymatic Dissociation Products (Collagenase, DNase, Elastase, Hyaluronidase, Papain, Trypsin), Enzymatic Dissociation Products, Instruments.
Global Cell Dissociation Market, By Tissue:
Based on the Tissue, Global Cell Dissociation Market is segmented as; Connective Tissues, Epithelial Tissues, Other type tissues (skeletal and muscles tissues).
Global Cell Dissociation Market, By Type:
Based on the Type, Global Cell Dissociation Market is segmented as; Cell detachment, Tissue dissociation.
Global Cell Dissociation Market, By End-User:
Based on the End-User, Global Cell Dissociation Market is segmented as; Pharmaceutical and Biotechnology companies, Research and Academics, other end users.
Global Cell Dissociation Market, By Region:
North America owns the biggest share of the market; this is due to the concentration of giant companies and growing research in Pharma and biopharma companies.
1. INTRODUCTION
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell Dissociation Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL DISSOCIATION MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
6.1. Enzymatic Dissociation Products
6.1.1. Collagenase
6.1.2. DNase
6.1.3. Elastase
6.1.4. Hyaluronidase
6.1.5. Papain
6.1.6. Trypsin
6.2. Enzymatic Dissociation Products
6.3. Instruments
7. GLOBAL CELL DISSOCIATION MARKET, BY TISSUE, 2019-2030 (USD MILLION)
7.1. Connective Tissues
7.2. Epithelial Tissues
7.3. Other type tissues (skeletal and muscles tissues)
8. GLOBAL CELL DISSOCIATION MARKET, BY TYPE, 2019-2030 (USD MILLION)
8.1. Cell detachment
8.2. Tissue dissociation
9. GLOBAL CELL DISSOCIATION MARKET, BY END-USER, 2019-2030 (USD MILLION)
9.1. Pharmaceutical and Biotechnology companies
9.2. Research and Academics
9.3. other end users
10. GLOBAL CELL DISSOCIATION MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. Abeomics
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. AcceGen
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Alstem
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Becton
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Biological Industries
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Capricorn Scientific
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Central Drug House
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Cytiva
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Dickinson and Company
Company details
Financial outlook
Product summary
Recent developments
11.10. Gemini Bio
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Genlantis
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Innovative Cell Technologies
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Miltenyi Biotec
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Neuromics
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. PromoCell GmbH
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. Roche Diagnostics
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. STEMCELL Technologies
11.17.1 Company details
11.17.2 Financial outlook
11.17.3 Product summary
11.17.4 Recent developments
11.18. Thermo Fisher Scientific
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. VitaCyte
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
11.20. Worthington Biochemical Corporation
11.20.1. Company details
11.20.2. Financial outlook
11.20.3. Product summary
11.20.4. Recent developments
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell Dissociation Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL DISSOCIATION MARKET, BY PRODUCT, 2019-2030 (USD MILLION)
6.1. Enzymatic Dissociation Products
6.1.1. Collagenase
6.1.2. DNase
6.1.3. Elastase
6.1.4. Hyaluronidase
6.1.5. Papain
6.1.6. Trypsin
6.2. Enzymatic Dissociation Products
6.3. Instruments
7. GLOBAL CELL DISSOCIATION MARKET, BY TISSUE, 2019-2030 (USD MILLION)
7.1. Connective Tissues
7.2. Epithelial Tissues
7.3. Other type tissues (skeletal and muscles tissues)
8. GLOBAL CELL DISSOCIATION MARKET, BY TYPE, 2019-2030 (USD MILLION)
8.1. Cell detachment
8.2. Tissue dissociation
9. GLOBAL CELL DISSOCIATION MARKET, BY END-USER, 2019-2030 (USD MILLION)
9.1. Pharmaceutical and Biotechnology companies
9.2. Research and Academics
9.3. other end users
10. GLOBAL CELL DISSOCIATION MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. Abeomics
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. AcceGen
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Alstem
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Becton
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Biological Industries
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Capricorn Scientific
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Central Drug House
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Cytiva
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Dickinson and Company
Company details
Financial outlook
Product summary
Recent developments
11.10. Gemini Bio
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Genlantis
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Innovative Cell Technologies
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Miltenyi Biotec
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Neuromics
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. PromoCell GmbH
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. Roche Diagnostics
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. STEMCELL Technologies
11.17.1 Company details
11.17.2 Financial outlook
11.17.3 Product summary
11.17.4 Recent developments
11.18. Thermo Fisher Scientific
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. VitaCyte
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
11.20. Worthington Biochemical Corporation
11.20.1. Company details
11.20.2. Financial outlook
11.20.3. Product summary
11.20.4. Recent developments
